{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["80"],"submitter":["Wimmer K"],"pubmed_abstract":["<h4>Background</h4>The Clinical Treatment Score post-5 years (CTS5) is a clinicopathological tool designed to estimate late distant recurrence (LDR) in hormone receptor-positive (HR+) breast cancer patients after 5 years of adjuvant endocrine therapy (ET). While intended as a prognostic algorithm, its predictive value for ET extension remains uncertain.<h4>Methods</h4>The score was calculated in 4931 patients from four prospective randomized ABCSG trials (ABCSG-6, -6a, -8, and -16) with 250 LDR events. We assessed its prognostic power, calibration accuracy, and predictive value. Time to LDR was analyzed using Cox regression models.<h4>Results</h4>In our cohorts, the CTS5 provided prognostic information whether used as a continuous or categorical score. In the ABCSG-8 cohort (n = 2054) and the combined ABCSG-6+8 cohort (n = 3308), a higher continuous score was significantly associated with increased LDR risk. The categorical CTS5 showed that high-risk patients had significantly higher LDR rates compared to low- or intermediate-risk patients. The score slightly overestimated LDR risk, regardless of predicted risk. Although no significant predictive value was found on the relative scale, an absolute LDR risk reduction of 23.4 % was found in patients with a high CTS5 of 5 when extended ET was administered additional five than two years. In patients with a CTS5 of 2, no benefit was found when ET was extended to 10 instead of 7 years.<h4>Conclusion</h4>The CTS5 is a valid tool for LDR risk stratification in HR + breast cancer, but should be used cautiously for determining benefits from ET extension, as no significant predictive value was found."],"journal":["Breast (Edinburgh, Scotland)"],"pagination":["104415"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11904565"],"repository":["biostudies-literature"],"pubmed_title":["Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials."],"pmcid":["PMC11904565"],"pubmed_authors":["Hlauschek D","Suppan C","Egle D","Fesl C","Jakesz R","Helfgott R","Halper S","Solkner L","Greil R","Fitzal F","Wimmer K","Balic M","Gampenrieder SP","Filipits M","Gnant M","Pfeiler G","Singer CF","Austrian Breast & Colorectal Cancer Study Group","Steger G"],"additional_accession":[]},"is_claimable":false,"name":"Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.","description":"<h4>Background</h4>The Clinical Treatment Score post-5 years (CTS5) is a clinicopathological tool designed to estimate late distant recurrence (LDR) in hormone receptor-positive (HR+) breast cancer patients after 5 years of adjuvant endocrine therapy (ET). While intended as a prognostic algorithm, its predictive value for ET extension remains uncertain.<h4>Methods</h4>The score was calculated in 4931 patients from four prospective randomized ABCSG trials (ABCSG-6, -6a, -8, and -16) with 250 LDR events. We assessed its prognostic power, calibration accuracy, and predictive value. Time to LDR was analyzed using Cox regression models.<h4>Results</h4>In our cohorts, the CTS5 provided prognostic information whether used as a continuous or categorical score. In the ABCSG-8 cohort (n = 2054) and the combined ABCSG-6+8 cohort (n = 3308), a higher continuous score was significantly associated with increased LDR risk. The categorical CTS5 showed that high-risk patients had significantly higher LDR rates compared to low- or intermediate-risk patients. The score slightly overestimated LDR risk, regardless of predicted risk. Although no significant predictive value was found on the relative scale, an absolute LDR risk reduction of 23.4 % was found in patients with a high CTS5 of 5 when extended ET was administered additional five than two years. In patients with a CTS5 of 2, no benefit was found when ET was extended to 10 instead of 7 years.<h4>Conclusion</h4>The CTS5 is a valid tool for LDR risk stratification in HR + breast cancer, but should be used cautiously for determining benefits from ET extension, as no significant predictive value was found.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T19:03:24.279Z","creation":"2025-04-04T03:02:25.367Z"},"accession":"S-EPMC11904565","cross_references":{"pubmed":["39985843"],"doi":["10.1016/j.breast.2025.104415"]}}